Impax Laboratories, Inc. company was founded in 1993 and is headquartered in Hayward, California. mpax Laboratories, Inc. engages in the development and commercialization of bioequivalent and brand-name pharmaceuticals. It operates through two divisions, Global Pharmaceuticals and Impax Pharmaceutical. The Global Pharmaceuticals division develops, formulates, manufactures, and sells controlled release and specialty generic pharmaceutical products. This division offers generic prescription products directly to wholesalers and large retail drug chains; and generic over-the-counter and generic prescription products through unrelated third-party pharmaceutical entities. The Impax Pharmaceutical division develops proprietary brand pharmaceutical products that address central nervous system disorders, including Alzheimer's disease, attention deficit hyperactivity disorder, depression, epilepsy, migraines, multiple sclerosis, Parkinson's disease, and schizophrenia. As of March 10, 2009, the company marketed 70 generic pharmaceuticals representing dosage variations of 24 different pharmaceutical compounds through its Global Pharmaceuticals division, as well as 16 products representing dosage variations of 4 different pharmaceutical compounds through its alliance agreements partners. Impax Laboratories markets and sells its generic pharmaceutical prescription drug products in the continental United States of America and the Commonwealth of Puerto Rico. It has alliance agreements with Teva Pharmaceutical Industries, Ltd.; Wyeth; Schering-Plough Corporation; and DAVA Pharmaceuticals, Inc.

De Novo Pharmaceuticals, Ltd. was incorporated in 1999 and is based in Cambridge, the United Kingdom. De Novo Pharmaceuticals, Ltd., a drug discovery company, provides computational drug design services. It focuses on small molecule therapeutics. The company provides services to drug discovery customers seeking progress from validated target to novel hits; and to medicinal chemistry groups interested in focused chemical libraries. It offers SkelGen, a chemical structure-generation platform and a suite of software tools for the analysis of structural information on a protein target and the de novo design of molecules to bind into its site, as well as for the hit and lead discovery to the pharmaceutical industry. The company offers its SkelGen for scaffold hopping, virtual high-throughput screening, focused library design, intelligent fragment linking, and low affinity fragment-based design applications. It also provides drug discovery partnerships, such as structure-based drug design, ligand-based drug design, and fragment-based drug design services, as well as focused libraries for medicinal chemistry seeking the design of focused libraries against classes of targets. In addition, the company involves in applying its SkelGen silico drug design platform to design compounds for various targets within the diabetes field.

Pharming Group N.V. is a Netherlands-based biotechnology company. The Company has facilities both in the Netherlands and the United States. Pharming develops products for the treatment of diseases with significant medical needs, including genetic disorders, diseases associated with the immune system, ageing diseases, and nutritional products. The Company’s technologies include platforms for the production of protein therapeutics and technology and processes for the purification and formulation of these products, as well as technologies in the field of DNA repair via its subsidiary DNage BV. Pharming products under development are divided into three categories: biopharmaceuticals, biomaterials, and bio-nutritionals. Products in the most advanced stage of development and closest to commercialization are Rhucin and human lactoferrin for use in food products. Pharming has several partnerships and collaborations with, inter alia, AgResearch, US Army, Aslan and Schering-Plough.

Blansett Pharmacal Co., Inc. company's products include respiratory drugs Prolex and Nalex, tension headache remedy Anolor, and swimmer's ear treatment Cortane. Blansett also makes medications for women's health and hemorrhoids. On top of developing its own products, the company markets under-promoted products developed by other pharmaceutical companies. Blansett Pharmacal was founded in 1982 in North Little Rock, Arkansas; its products are distributed throughout the US.

Kyowa Hakko Kirin Co., Ltd., formerly KYOWA HAKKO KOGYO CO., LTD., is a Japan-based manufacturer that has five business segments. The Medical Product segment is engaged in the manufacture, sale and promotion of medical products for hospital use, as well as the provision of technologies for antibody drug creation, the development of candidate substances for new drugs and the supply of clinical test reagents. The Biochemical segment offers medical and industrial materials, mainly amino and nucleic acids, as well as healthcare items and products for agriculture and fishery uses. It also designs and constructs facilities. The Chemical Product segment provides solvents, plasticizers, materials for plasticizers and functional products, among others. Its Food segment supplies seasonings, materials for confectionery and bread making, processed food products and others. The Others segment is involved in the wholesale and distribution businesses, as well as the provision of industrial alcohol.

Questcor Pharmaceuticals, Inc. was founded in 1990 and is headquartered in Union City, California. Questcor Pharmaceuticals, Inc., a specialty pharmaceutical company, provides prescription drugs for central nervous system disorders. The company markets H.P. Acthar Gel (repository corticotropin injection), an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with multiple sclerosis, and the treatment of nephrotic syndrome. H.P. Acthar Gel is also used in treating patients with infantile spasms, a rare form of refractory childhood epilepsy; and opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological disorder. The company also markets Doral (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings.

Arnet Pharmaceutical manufactures private-label nutritional supplements. Arnet Pharmaceutical Corp. products range from daily vitamins and herbal extracts to minerals and amino acids. The company's capabilities include making tablet, capsule, powder, and chewable products. As a contract manufacturer, Arnet will work from customer-provided formulations or formulate products themselves. It also produces blended products such as Osteoporex, a calcium blend to address osteoporosis, and Gluthatione, an antioxidant supplement to increases energy and reduces stress. Founded in 1972, Arnet's customers span across more than 50 countries.

Launched in 1982 with a single product, Pharmadass (through subsidiary HealthAid) sells more than 450 products: vitamins and minerals, beauty care items, weight-loss formulas, and aromatherapy oils. It also sells anti-smoking products, herbal cigarettes, anti-snoring spray, and such supplements as fish oils and bee products. Specialty lines focus on such areas as mood enhancement, women's health, the immune system, and vitality. Pharmadass products are found in about 4,000 pharmacies and health food stores in the UK and in 30 countries worldwide.

Pacira Pharmaceuticals, Inc. company develops sustained-release therapies based on DepoFoam, an injectable drug delivery technology that allows both immediate and sustained release. Its two marketable products are DepoCyt for treating cancer-related neoplastic meningitis and DepoDur for the treatment of post-operative pain. Pacira's lead candidate is EXPAREL, an injectable local anesthetic. The company has two manufacturing facilities that make its Depo products. Once the injectables subsidiary of drug-delivery company SkyePharma PLC, Pacira was bought out in 2007 by an investor group led by MPM Capital, OrbiMed, HBM Bioventures, and Sanderling Ventures.

Amylin Pharmaceuticals was founded in 1987 and is based in San Diego, California. Amylin Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases. As of December 31, 2008, the Company was marketing two medicines to treat diabetes: BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection. In addition to its marketed products, the Company is working with Eli Lilly and Company (Lilly) and Alkermes, Inc. (Alkermes) to develop exenatide once weekly. The Company maintains a discovery research program focused on peptide and protein therapeutics.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.